{"podcast":{"title":"The BioHub - by Avetix","slug":"the-biohub-by-avetix-7252289","podcast_index_feed_id":7252289,"rss_url":"https://anchor.fm/s/f0076084/podcast/rss","website_url":"https://podcasters.spotify.com/pod/show/max-brennan4","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40170153/40170153-1775724702970-e7a36a5e3cf58.jpg","author":"Max Brennan - Biotech HeadHunter","episode_count":230,"summary":"Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Subscribe now and be part of the conversation that's shaping the future of biotechnology. Get ready for an immersive experience into the world of biotech with The BioHub.","last_synced_at":"2026-07-21T04:19:24.893516+00:00","page_url":"https://stenobird.com/podcast/the-biohub-by-avetix-7252289"},"episode":{"title":"Episode 179 - Tosh Butt - CEO of Navigator Medicines","slug":"episode-179-tosh-butt-ceo-of-navigator-medicines","published_at":"2026-05-26T10:39:10+00:00","page_url":"https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-179-tosh-butt-ceo-of-navigator-medicines","show_page_url":"https://stenobird.com/podcast/the-biohub-by-avetix-7252289","url":"https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-179---Tosh-Butt---CEO-of-Navigator-Medicines-e3jtha0","audio_url":"https://anchor.fm/s/f0076084/podcast/play/120554240/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-26%2F424905945-44100-2-eb4ee81fde178.mp3","summary":"Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa. Giving us the full picture, from NAV-240's Korean-origins &amp; the 2024 $100million Series A lead by RA Capital &amp; Forbion, to the work that went into their half-life extended next-gen molecule NAV-242 &amp; the speedy clinical development plan that could lead to a step change in HS patient outcomes. We also discuss Tosh's learnings from a career in big pharma across the likes of GSK &amp; AZ, why he had to 'scratch' his biotech 'itch' &amp; the career learnings he's taking into his role at Navigator.","meta_description":"Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa. Giving us the full picture, from NAV-240's Ko…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1807,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-179-tosh-butt-ceo-of-navigator-medicines/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-179-tosh-butt-ceo-of-navigator-medicines.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}